EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Extracellular vesicles and the lung: from disease pathogenesis to biomarkers and treatments

Kyong-Su Park iD, Cecilia Lässer iD, Jan Lötvall iD

Physiological Reviews · 01.07.2025 · 105 (3) · 1733-1821

DOI: 10.1152/physrev.00032.2024 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Physiological Reviews, erschienen am 01.07.2025. Verfasst von Kyong-Su Park und 2 weiteren Autor:innen. Beteiligte Einrichtung: Krefting Research Centre, Institute of Medicine at the Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden. Hauptthemen laut MEDLINE: Extracellular Vesicles, Lung, Lung Diseases. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 600 Literaturangaben. Gefördert von: Hjärt-Lungfonden (Swedish Heart-Lung Foundation), Vetenskapsrådet (VR), Swedish Cancer Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nanosized extracellular vesicles (EVs) are released by all cells to convey cell-to-cell communication. EVs, including exosomes and microvesicles, carry an array of bioactive molecules, such as proteins and RNAs, encapsulated by a membrane lipid bilayer. Epithelial cells, endothelial cells, and various immune cells in the lung contribute to the pool of EVs in the lung microenvironment and carry molecules reflecting their cellular origin. EVs can maintain lung health by regulating immune responses, inducing tissue repair, and maintaining lung homeostasis. They can be detected in lung tissues and biofluids such as bronchoalveolar lavage fluid and blood, offering information about disease processes, and can function as disease biomarkers. Here, we discuss the role of EVs in lung homeostasis and pulmonary diseases such as asthma, chronic obstructive pulmonary disease, cystic fibrosis, pulmonary fibrosis, and lung injury. The mechanistic involvement of EVs in pathogenesis and their potential as disease biomarkers are discussed. Finally, the pulmonary field benefits from EVs as clinical therapeutics in severe pulmonary inflammatory disease, as EVs from mesenchymal stem cells attenuate severe respiratory inflammation in multiple clinical trials. Further, EVs can be engineered to carry therapeutic molecules for enhanced and broadened therapeutic opportunities, such as the anti-inflammatory molecule CD24. Finally, we discuss the emerging opportunity of using different types of EVs for treating severe respiratory conditions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Extracellular VesiclesLungLung DiseasesHumansBiomarkersAnimals

Stichwörter der Autor:innen

airwaysexosomesmicroparticlesmicrovesiclespulmonary

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Krefting Research Centre, Institute of Medicine at the Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden.

ORCID-Profile: Kyong-Su Park, Cecilia Lässer, Jan Lötvall

Förderung

  • Hjärt-Lungfonden (Swedish Heart-Lung Foundation)
  • Vetenskapsrådet (VR)
  • Swedish Cancer Foundation

Zitieren

APA

Park, K. S., Lässer, C., & Lötvall, J. (2025). Extracellular vesicles and the lung: from disease pathogenesis to biomarkers and treatments. Physiological Reviews, 105(3), 1733-1821. https://doi.org/10.1152/physrev.00032.2024

Vancouver

Park KS, Lässer C, Lötvall J. Extracellular vesicles and the lung: from disease pathogenesis to biomarkers and treatments. Physiological Reviews. 2025;105(3):1733-1821. doi:10.1152/physrev.00032.2024

BibTeX
@article{Park2025,
  author = {Park, Kyong-Su and Lässer, Cecilia and Lötvall, Jan},
  title = {Extracellular vesicles and the lung: from disease pathogenesis to biomarkers and treatments},
  journal = {Physiological Reviews},
  year = {2025},
  volume = {105},
  number = {3},
  pages = {1733--1821},
  doi = {10.1152/physrev.00032.2024}
}
Kostenlos starten →